Halozyme Therapeutics (HALO) Earnings Date & Reports
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies... Show more
HALO is expected to report earnings to rise 13.12% to $1.81 per share on August 11
Halozyme Therapeutics (HALO) Q1 2026 Earnings Recap: Beats on Revenue and EPS Amid Strong Royalty Growth
Key Takeaways
- Halozyme Therapeutics reported Q1 2026 total revenue of $376.7 million, up 42% year-over-year and beating consensus estimates of $355.1 million.
- Royalty revenue surged 43% to $240.7 million, driven by ENHANZE partner products like DARZALEX SC, VYVGART Hytrulo, and Phesgo.
- Adjusted EPS came in at $1.60, exceeding estimates of $1.52 by 5.3%.
- Adjusted EBITDA reached $229.5 million, 7.2% above expectations.
- Company announced a new $1 billion share repurchase program, with at least $400 million planned for 2026.
- Reiterated full-year 2026 guidance, with total revenue projected at $1.71-$1.81 billion.
Earnings Context and Why It Matters
Halozyme Therapeutics (HALO), a biopharmaceutical platform company, reported first quarter results for the period ended March 31, 2026, showcasing robust growth in its ENHANZE drug delivery technology. This earnings release is pivotal as it validates the company's royalty-driven model amid expanding partnerships with major pharma firms like Janssen, argenx, and Roche. With blockbuster products leveraging ENHANZE for subcutaneous delivery, investors are focused on sustained royalty momentum and pipeline progress. Recent acquisitions like Hypercon and Surf Bio diversify revenue streams, positioning Halozyme for long-term growth in oncology and beyond. Strong results reinforce HALO's appeal in a biotech sector grappling with patent cliffs and innovation demands.
Halozyme delivered standout Q1 2026 performance. Total revenue hit $376.7 million, surpassing consensus estimates of $355.1 million by 6.1% and rising 42% from $264.9 million in Q1 2025. Royalty revenue, the core growth driver, climbed 43% to $240.7 million from $168.2 million year-over-year, fueled by higher sales of ENHANZE-enabled drugs including DARZALEX SC (Janssen), VYVGART Hytrulo (argenx), and Phesgo (Roche).
Adjusted EPS registered $1.60, beating expectations of $1.52 by 5.3% and improving from $1.11 in the prior year. Adjusted EBITDA expanded to $229.5 million (60.9% margin), topping estimates of $214 million by 7.2%. GAAP net income rose to $150.0 million, with diluted EPS at $1.22, up from $0.93 year-over-year. All key metrics exceeded forecasts, highlighting operational strength and partner product uptake.
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener today to enhance your investment strategy.
Market Reaction and Investor Sentiment
HALO shares rose about 3.6% intraday to $66.41 following the earnings release, with after-hours gains around 1.5-3.6% reflecting positive investor response to the beats and $1B buyback announcement. Sentiment turned bullish, buoyed by royalty acceleration and capital return plans, though tempered by full-year EPS guidance midpoint slightly below consensus ($8.00 vs. $8.09). Trading volume spiked, signaling strong interest.
Forward Outlook and Key Factors to Monitor
Halozyme reiterated its 2026 guidance, projecting total revenue of $1.71-$1.81 billion (22-30% growth), royalty revenue of $1.13-$1.17 billion (30-35% growth), adjusted EBITDA of $1.125-$1.205 billion, and non-GAAP diluted EPS of $7.75-$8.25. This underscores confidence in ENHANZE's trajectory, with nine products in development (aiming for 13 by year-end) and recent deals like Vertex, Oruka, and GSK adding firepower.
Investors should watch partner milestones, such as potential launches from TAK-881 data and expansions in Hypercon (five agreements for 17 targets, first approvals ~2030). Royalty trends from key blockbusters remain critical, alongside manufacturing ramp-ups for API sales. The $1B repurchase program, targeting $400M in 2026, signals robust cash flow (~$550M expected free cash flow) and shareholder focus.
New collaborations signal pipeline depth, but execution risks in clinical trials and regulatory approvals warrant attention. Broader biotech dynamics, including oncology demand and subcutaneous delivery adoption, will shape trajectory. Monitor Q2 results for sustained momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets
Industry Biotechnology